Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi

Sodium-glucose cotransporters: new targets of cancer therapy? (CROSBI ID 257651)

Prilog u časopisu | pregledni rad (znanstveni) | međunarodna recenzija

Vrhovac Madunić, Ivana ; Madunić, Josip ; Breljak, Davorka ; Karaica, Dean ; Sabolić, Ivan Sodium-glucose cotransporters: new targets of cancer therapy? // Arhiv za higijenu rada i toksikologiju, 69 (2018), 4; 278-284. doi: 10.2478/aiht-2018-69-3204

Podaci o odgovornosti

Vrhovac Madunić, Ivana ; Madunić, Josip ; Breljak, Davorka ; Karaica, Dean ; Sabolić, Ivan

engleski

Sodium-glucose cotransporters: new targets of cancer therapy?

Glucose, the key source of metabolic energy, is imported into cells by two categories of transporters: 1) facilitative glucose transporters (GLUTs) and 2) secondary active sodium- glucose cotransporters (SGLTs). Cancer cells have an increased demand for glucose uptake and utilisation compared to normal cells. Previous studies have demonstrated the overexpression of GLUTs, mainly GLUT1, in many cancer types. As the current standard positron emission tomography (PET) tracer 2- deoxy-2-(18 F)fluoro-D-glucose (2-FDG) for imaging tumour cells via GLUT1 lacks in sensitivity and specificity, it may soon be replaced by the newly designed, highly sensitive and specific SGLT tracer α-methyl-4-(F- 18)fluoro-4- deoxy-D- glucopyranoside (Me-4FDG) in clinical detection and tumour staging. This tracer has recently demonstrated the functional activity of SGLT in pancreatic, prostate, and brain cancers. The mRNA and protein expression of SGLTs have also been reported in colon/colorectal, lung, ovarian, head, neck, and oral squamous carcinomas. So far, SGLTs have been poorly investigated in cancer, and their protein expression and localisation are often controversial due to a lack of specific SGLT antibodies. In this review, we describe current knowledge concerning SGLT1 and SGLT2 (over)expression in various cancer types. The findings of SGLTs in malignant cells may help in developing novel cancer therapies with SGLT2 or SGLT1/SGLT2 inhibitors already used in diabetes mellitus treatment.

brain cancer ; Na+-dependent glucose transporters ; pancreatic cancer ; positron emission tomography ; prostate cancer ; SGLT inhibitors

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o izdanju

69 (4)

2018.

278-284

objavljeno

0004-1254

1848-6312

10.2478/aiht-2018-69-3204

Povezanost rada

Biologija

Poveznice
Indeksiranost